Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    nb-001 ...
  • Study Participants

Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
Study Started
Feb 28
Primary Completion
Dec 31
Study Completion
Dec 31
Last Update
May 30

Drug NB-001


Inclusion Criteria:

18 to 80 years of age of either gender
Good general health
History of recurrent herpes labialis with at least 3 episodes per year

Exclusion Criteria:

Pregnant and/or nursing female
Lesions or irritation on or around the lips that would interfere with recognition of a herpes labialis attack
Treatment with topical steroids, antivirals, or new topical products on or around the lips in the week prior to the onset of an attack
Known allergies to topical creams, ointments or medications.

Other protocol-defined inclusion/exclusion criteria may apply
No Results Posted